{
    "clinical_study": {
        "@rank": "134434", 
        "arm_group": [
            {
                "arm_group_label": "Pembrolizumab Low Dose", 
                "arm_group_type": "Experimental", 
                "description": "Participants receive pembrolizumab intravenously (IV) on Day 1 of each cycle"
            }, 
            {
                "arm_group_label": "Pembrolizumab Higher Dose", 
                "arm_group_type": "Experimental", 
                "description": "Participants receive pembrolizumab intravenously (IV) on Day 1 of each cycle"
            }, 
            {
                "arm_group_label": "Pembrolizumab Higher dose/cisplatin/pemetrexed", 
                "arm_group_type": "Experimental", 
                "description": "Participants receive pembrolizumab intravenously (IV) on Day 1 of each cycle, and cisplatin and pemetrexed per institutional standard."
            }, 
            {
                "arm_group_label": "Pembrolizumab Higher Dose/carboplatin/paclitaxel", 
                "arm_group_type": "Experimental", 
                "description": "Participants receive pembrolizumab intravenously (IV) on Day 1 of each cycle, and carboplatin and paclitaxel per institutional standard."
            }
        ], 
        "brief_summary": {
            "textblock": "This study using pembrolizumab (MK-3475) will be done in 2 parts.  In Part A successive\n      participant cohorts with advanced solid tumors will receive pembrolizumab to find the best\n      dose level for Part B.  If no tolerable dose is found, Part B will not begin. In Part B\n      participants with advanced non-small cell lung cancer (NSCLC)  will receive pembrolizumab in\n      combination with either cisplatin/pemetrexed or carboplatin/paclitaxel by non-random\n      assignment to assess the safety and tolerability of the combination therapy."
        }, 
        "brief_title": "Study of Pembrolizumab (MK-3475) Monotherapy in Participants With Advanced Solid Tumors and Pembrolizumab Combination Therapy in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Solid Tumor", 
            "Non-small Cell Lung Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  In Part A: histological or cytological diagnosis of solid tumor, progressive\n             metastatic disease, or progressive locally advanced disease not amenable to local\n             therapy\n\n          -  In Part B: histologically- or cytologically-confirmed diagnosis of NSCLC (Stage\n             IIIB/IV)\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n\n          -  Adequate organ function\n\n        Exclusion criteria:\n\n          -  Cancer therapy within 4 weeks prior to the first dose of study therapy, or not\n             recovered from the adverse events of agents administered more than 4 weeks prior to\n             the first dose of study therapy.\n\n          -  Currently participating or has participated in a study with an investigational agent\n             or using an investigational device within 30 days of first dose of study therapy\n\n          -  Expected to require any other form of antineoplastic therapy while on study\n\n          -  On chronic systemic steroid therapy within two weeks prior to the first dose of trial\n             treatment or on any other form of immunosuppressive medication"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01840579", 
            "org_study_id": "3475-011"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Pembrolizumab Low Dose", 
                    "Pembrolizumab Higher Dose", 
                    "Pembrolizumab Higher dose/cisplatin/pemetrexed", 
                    "Pembrolizumab Higher Dose/carboplatin/paclitaxel"
                ], 
                "intervention_name": "Pembrolizumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Pembrolizumab Higher dose/cisplatin/pemetrexed", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Pembrolizumab Higher dose/cisplatin/pemetrexed", 
                "intervention_name": "Pemetrexed", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Pembrolizumab Higher Dose/carboplatin/paclitaxel", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Pembrolizumab Higher Dose/carboplatin/paclitaxel", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pemetrexed", 
                "Cisplatin", 
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 2, 2014", 
        "location": {
            "contact": {
                "last_name": "Japan Call Center", 
                "phone": "81-3-6272-1957"
            }, 
            "facility": {
                "address": {
                    "city": "Chiyoda-Ku, Tokyo", 
                    "country": "Japan", 
                    "zip": "102-8667"
                }, 
                "name": "MSD K.K."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase I Study of MK-3475 Alone in Subjects With Advanced Solid Tumors and in Combination With Cisplatin/Pemetrexed or Carboplatin/Paclitaxel in Subjects With Advanced Non-Small Cell Lung Cancer", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants experiencing dose-limiting toxicities (DLTs)", 
            "safety_issue": "Yes", 
            "time_frame": "Cycle 1 (first dose up to 4 weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01840579"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}